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ABSTRACT:
Research Problem: What are the factors responsible
for decreased incidence of coronary artery disease in
epileptics?
Objectives: To evaluate the effect of phenytoin on
lipid profile parameters in epileptics and to discuss its
implications.
Study Design: Prospective study.
Setting: Neurology clinic of Medicine Department of
a teaching hospital.
Participants: Randomly selected epileptic patient at-
tending neurology clinic and admitted to inpatient
department of J. N. Medical College Hospital.
Sample Size: 56 epileptic patients.
Study Variables: Phenytoin therapy, lipid profile pa-
rameters.
Statistical Analysis: By test of significance.
Result: No significant change in serum levels of total
cholesterol, LDL - C, VLDL - C, triglycerides and
phospholipids was observed with phenytoin therapy
during study. However, serum HDL - C showed a
significant increase, both at 12 weeks and 24 weeks (
P 0.001) of therapy.
Conclusion: Phenytoin, a commonly used
anticonvulsive drug, increases serum HDL - C level
significantly, while there is no significant change in
other parameters of lipid profile. This rise in HDL - C
may provide protection to epileptic patients against
atherogenic vascular diseases including coronary ar-
tery disease.
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INTRODUCTION:
Epilepsy forms one of the major public health
problems in our .country and is the largest group
requiring long-term anticonvulsive therapy. Though
these patients come out of agony, they are predis-
posed to various untowards effects' including abnor-
malities in serum lipid and lipoproteins with possible
implication of atherogenetic vascular diseases like
coronary artery disease 2,3, ischaemic cerebrovascu-
lar diseases 4,5 and peripheral vascular. diseases6•
However, the clinicians working on epilepsy have
reported decreased incidence of coronary arstery dis-
ease in epileptics on long-term anticonvulsive therapy
but with conflicting results. The present study was,
therefore, undertaken to evaluate the effect of
phenytoin on various parameters oflipid profile and to
discuss-its implications.
MATERIAL AND METHODS:
The study comprised of 56 newly diagnosed
epileptic patients attending Neurology Clinic or ad-
mitted in inpatient department of Medicine who were
randomly selected for the study. They were placed on
phenytoin 200 - 300 mg. / day orally and 5 ml venous
blood was collected after overnight fasting for estima-
tion of various parameters of lipid profile at basal
level, 12 weeks and 24 weeks of therapy .25 comparable
subjects served as control. '
OBSERVATIONS:
Out of 56 cases, 75% were males and 25% were
females. The maximum number of cases were in 11-20
years age group with mean age of 24.22 years (Table
- I). Majority of t~e patients (59%) presented within
one year of attack (Table- II) and had primary
general ised seizures.
No significant change in levels of various
parameters of lipid profile was observed in study
group before starting the therapy as compared to the
control group, thus, showing that epilepsy perse does
not produce any dyslipidemia.
With phenytoin therapy, no significant change
was observed in levels of total serum cholesterol, LDL
- C, VLDL- C, triglyceride and phospholipids. Serum
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HDL - C level, however, showed a significant increase
both at 12 weeks and 24 weeks of therapy. The ri se in
level of HDL - C was 14.5%, (males - 16.22% and
females - 9.59%) at 12 weeks and 18.63% (males -
19.27%, females - 16.76%) at 24 weeks of therapy as
compared to the basal level. Six of our patients failed
to show any change in parameters of lipid profile.
DISCUSSION:
Epilepsy is a major public health problem re-
quiring long-term therapy, resulting in large number of
untoward effects I . Various studies have been carried
out to study untoward effects in epileptics on long-
term anticonvulsive therapy 2.3.4.5.6. However, clini-
cians working on epilepsy have shown a decreased
incidence of coronary artery disease in patient of
epilepsy receiving long-term anticonvulsive therapy
7.8.9 but with conflicting results 10.
The present observations of significant in-
crease in HDL - C with insignificant changes in other
TABLE-I
parameters of lipid profile in epileptic patients on
long-term phenytoin therapy is consistent with stud-
ies of other authors. I 1.12.13.14
Exact mechanism by which phenytoin in-
creases HDL - C is poorly understood but induction of
microsomal enzyme system in liver may be an impor-
tant factor in determining the plasma lipid concentra-
tion.ls
CONCLUSION:
The following conclusions can be drawn from
the present study:
I. Phenytoin increases significantly serum HDL
- C level while there is no significant change
in other lipid parameters.
2. The rise in HDL - C may be genetically deter-
mined.
3. Rise in HDL- C may provide protection to
epileptic patients against atherogenic vascu-
lar diseases, including coronary artery dis-
ease.
AGE AND SEX DISTRIBUTION OF CASES AND CONTROL
Age group Study group Control group
(years) Male Female Total % Male Female Total 0/0
11-20 20. 4 24 42.86 9 3 12 48.0
21-30 14 6 20 35.71 4 3 7 28.0
31-40 8 2 10 17.86 3 2 5 20.0





DISTRIBUTION OF CASES ACCORDING TO DURATION OF ILLNESS
Duration No. of patients 0/0
(in years)
0- I 33 59.1
I - 2 15 26.8
2 - 3 8 14.2.
TOTAL
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TABLE-III
LIPID PROFILE IN CONTROL AND STUDY GROUPS BEFORE STARTING PHENYTOIN TREATMENT
Group Total serum HDL-C LDL-C VLDL-C Triglyceride Phospholipid
cholesterol
I Control group 186:1:23.25 50.04:1:43.61 1I4.8:1:2I.I 3 21.52:1:1.53 107.76:1:7.42 200:1:33.17
(n=25)
A.Male 189.65 :1:26.83 49.41:1:3.67 118:1:24.51 22:1:1.8 110:1:8.77 199.17:1:30.92
(n=J7)
B.Female 178.25:1:22.47 51.37:1:3.14 108:1:12.57 20.5:1:0.71 103:1:3.54 201.75:1:39.76
(n=8)
II Study group 192.46:1:31.23 53.28:1:6.98 118.82:1:24.38 20.5:1:6.38 102.61 :1:31.61 193.21:1:25.92
(n=56)
A.Male 192.95:1:30.89 53.14:1:6.89 119.48:1:24.5 20.43:1:6.87 101.95:1:34.07 193.95:1:22.12
(n=42)



















Values in mg/dl (mean • SD) (NS: Not significant)
TABLE-IV











I Zero week 192.46:1:31.23 53.28:1:6.98 118.82:1:24.38 20.50:1:6.38 102.61 :1:31.61 193.21 :1:25.92
(n=56)
A.Male 192.95:1:30.89 53.14:1:6.89 119.48:1:24.5 20.43:1:6.87 101.95:1:34.07 193.95:1:22.12
(n=42)
B.Male 191:1:34.75 53.71:1:7.82 116.86:1:25.99 20.71:1:5.06 104.57:1:25.03 191:1:37.32
(n=J4)
II 12 weeks 201.43:1:31.46 61.03:1:11.27 120.18:1:24.97 2I.11:1:4.16 104.64:1:20.71 195.32:1:33.4
(n=42)
A.Male 202.05:1:31.54 61.76:1:12.54 120.52:1:24.19 21.05:1:4.35 103.76:1:21.73 195.09:1:35.16
(n=42)
B.Female 199.5:1:33.72 58.86:1:6.89 119.14:1:29.25 21.28:1:3.81 107.28:1:18.84 196:1:30
(n=J4)
Values in mg / dl (Mean. SD) (NS : Not significant)
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TABLE-V
LIPID PROFILE IN STUDY GROUP AFTER 24 WEEKS OF PHENYTOIN TREATMENT
Study Total serum HDL-C LDL-C VLDL-C Triglyceride Phospholipid
group cholesterol
I Zero week 192.46 :t31.23 53.28:t6.98 118.82:!:24.38 20.50:t6.38 102.61 :t31.61 1.93.21:!:25.92
(n=56)
A.Male 192.95:t30.89 53.14:t6.89 119.48:!:24.5 20.43:t6.87 101.95:t34.07 193.55:!:22.12
(n=42)
B.Male 191:t34.75 53.7l:t7.82 116.86:!:25.99 20.7l:t5.06 104.57:!:25.03 191:t37.32
(n=/4)
1124 weeks 202.68:!:28.96 63.21 :t9.89 118.36:!:23.97 21.32:t4.14 106.53:t19.29 203.25:!:24.61
(n=56)
A.Male 202. 19:t30.21 63.38:t11.04 118.14:!:24.88 21.09:t4.53 105.14:!:22.28 2052:!:25.94
(n=42)



















Values in mg / dl (Mean • SD) (NS Not significant)
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